174680-67-2

Basic information

• Product Name: N-(5-broMopyrazin-2-yl)acetaMide
• Synonyms: N-(5-broMopyrazin-2-yl)acetaMide
• CAS NO: 174680-67-2
• Molecular Formula: C6H6BrN3O
• Molecular Weight: 216.03534
• Mol File: 174680-67-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 376.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.726±0.06 g/cm3(Predicted)
• PKA: 12.01±0.70(Predicted)
• CAS DataBase Reference: N-(5-broMopyrazin-2-yl)acetaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-broMopyrazin-2-yl)acetaMide(174680-67-2)
• EPA Substance Registry System: N-(5-broMopyrazin-2-yl)acetaMide(174680-67-2)

Safety Data

• Hazardous Substances Data: 174680-67-2(Hazardous Substances Data)

Upstream product

• 59489-71-3 5-amino-2-bromopyrazine 
• 108-24-7 acetic anhydride 
• 75-36-5 acetyl chloride 

Relevant articles and documents

SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS

There are disclosed compounds of the following formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating inflammatory and autoimmune diseases or disorders.

SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R4, R6, X, Y and Z are as defined herein. The compounds of Formula (I) have been found to act as glucokinase activators. Consequently, the compounds of Formula (I) and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucokinase.

BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR

The present invention provides a novel benzene derivative or thiophene derivative useful as a VAP-1 inhibitor, or a medicament for the prophylaxis or treatment of a VAP-1 associated disease and the like, namely, a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof.